OSTEOGENESIS IMPERFECTA

Osteogenesis Imperfecta — 'brittle bone disease' spanning a severity spectrum from occasional fractures to perinatal lethality, where the specific type I collagen variant determines prognosis, treatment approach, and recurrence risk for future pregnancies.

Whole genome sequencing evaluates COL1A1, COL1A2, and all 20+ additional OI-related genes — providing the molecular diagnosis that determines OI type classification, severity prognosis, and inheritance pattern for genetic counseling.

COL1A1
COL1A2

About this condition

Osteogenesis Imperfecta

Osteogenesis imperfecta (OI) is a group of heritable connective tissue disorders primarily caused by pathogenic variants in COL1A1 (chromosome 17q21.33) or COL1A2 (chromosome 7q21.3), encoding the α1 and α2 chains of type I collagen respectively. Type I collagen is the most abundant structural protein in bone, skin, tendons, and sclerae. OI is classified into types I-V (Sillence classification) based on clinical severity, with additional molecular subtypes (types VI-XX) defined by variants in non-collagenous genes involved in collagen processing, bone mineralization, and osteoblast function. Overall prevalence is approximately 1 in 10,000-20,000.

OI type I (mild, quantitative collagen deficiency from null COL1A1 alleles) causes bone fragility with blue sclerae, near-normal stature, and fractures that decrease after puberty. Type II (perinatal lethal) causes multiple in utero fractures, severe skeletal deformity, and death in the perinatal period. Type III (progressive deforming) causes severe bone fragility, progressive skeletal deformity, very short stature, and wheelchair dependence. Type IV (moderate) falls between types I and III. The specific COL1A1/COL1A2 variant — particularly whether it causes a quantitative deficiency (haploinsufficiency, typically milder) vs. a structural defect (glycine substitution in the collagen triple helix, typically more severe) — is the primary determinant of disease severity.

Treatment includes cyclic intravenous bisphosphonates (pamidronate, zoledronate − standard of care for moderate-severe OI, increasing bone density and reducing fracture rate), orthopedic management including intramedullary rodding of long bones, physical therapy, and hearing assessment (progressive hearing loss occurs in ~50% of adults with OI). Newer therapies in development include anti-sclerostin antibodies (romosozumab), anti-RANKL therapy (denosumab, showing benefit in pediatric OI studies), and gene therapy approaches targeting dominant-negative COL1A1/COL1A2 alleles.

Recessive OI (types VI-XX) is caused by variants in non-collagenous genes including SERPINF1, CRTAP, P3H1, PPIB, BMP1, IFITM5, and others — these are missed by COL1A1/COL1A2-only testing.

Gene locus: COL1A1 (17q21.33), COL1A2 (7q21.3), plus 20+ additional genes for recessive forms

COL1A1 and COL1A2 account for ~85-90% of OI, but 20+ additional genes cause recessive and atypical forms. Single-gene testing misses recessive OI. Whole genome sequencing evaluates the complete molecular landscape.

The specific collagen variant type — haploinsufficiency vs. glycine substitution — determines severity prognosis

COL1A1 null alleles (frameshift, nonsense, splice site variants that produce premature stop codons) cause quantitative collagen deficiency — typically mild OI type I with blue sclerae and reduced fracture risk after puberty. In contrast, glycine substitutions in the Gly-X-Y repeat of the collagen triple helix (particularly in the α1 chain C-terminal region) cause structural collagen defects that produce moderate to severe OI (types II-IV). This genotype-severity correlation enables prognostic counseling at the time of molecular diagnosis — information that is not available from clinical assessment alone in a newborn or fetus with a prenatal fracture.

Prenatal fractures on ultrasound can be OI type II (lethal) or type III (survivable) — molecular diagnosis distinguishes them

Prenatal ultrasound may detect multiple fractures, shortened limbs, or thoracic hypoplasia in the second trimester. The critical clinical question is whether this represents OI type II (perinatal lethal, typically caused by de novo dominant COL1A1/COL1A2 glycine substitutions) or OI type III (severe but survivable, also caused by collagen structural defects). The distinction has profound implications for management counseling. Molecular diagnosis from amniocentesis or CVS can identify the specific variant and — based on published genotype-phenotype data — provide evidence-based severity prediction that ultrasound alone cannot supply.

Osteogenesis Imperfecta — 'brittle bone disease' spanning a severity spectrum from occasional fractures to perinatal lethality, where the specific type I collagen variant determines prognosis, treatment approach, and recurrence risk for future pregnancies.

Osteogenesis Imperfecta

COL1A1 and COL1A2 account for ~85-90% of OI, but 20+ additional genes cause recessive and atypical forms. Single-gene testing misses recessive OI. Whole genome sequencing evaluates the complete molecular landscape.

The specific collagen variant type — haploinsufficiency vs. glycine substitution — determines severity prognosis

Prenatal fractures on ultrasound can be OI type II (lethal) or type III (survivable) — molecular diagnosis distinguishes them

Others in Rare Diseases

One test. A lifetime of answers.